Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placebo
ApprovedCompleted 3 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastric Motility Disorder
Conditions
Gastric Motility Disorder
Trial Timeline
Nov 1, 2009 → Feb 1, 2010
NCT ID
NCT01055704About Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placebo
Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placebo is a approved stage product being developed by Pfizer for Gastric Motility Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01055704. Target conditions include Gastric Motility Disorder.
What happened to similar drugs?
4 of 20 similar drugs in Gastric Motility Disorder were approved
Approved (4) Terminated (3) Active (14)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01055704 | Approved | Completed |
Competing Products
20 competing products in Gastric Motility Disorder